Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) have earned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $28.7143.

A number of equities analysts recently issued reports on the stock. Zacks Research upgraded shares of Cullinan Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Wedbush lifted their target price on shares of Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. New Street Research set a $26.00 price target on shares of Cullinan Therapeutics in a report on Thursday, November 20th. HC Wainwright raised their price target on shares of Cullinan Therapeutics from $26.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, BTIG Research boosted their price objective on shares of Cullinan Therapeutics from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, November 24th.

Key Cullinan Therapeutics News

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Zacks upgraded Cullinan from “hold” to “strong-buy,” which can attract momentum and retail flows into the shares. Zacks Research Upgrade
• Positive Sentiment: Technical/momentum coverage notes a big jump in the stock’s Relative Strength (RS) rating to 91 — a sign some quant/momentum-focused investors may increase exposure. Stocks to watch: Cullinan Therapeutics sees RS rating jump to 91
• Neutral Sentiment: Coverage pieces outline what could sustain recent price strength (pipeline progress and upcoming clinical data), but they frame these as potential catalysts rather than confirmed drivers — meaning upside depends on execution. Here’s What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength
• Neutral Sentiment: Analyst-comment roundup / industry insight coverage mentions Cullinan among healthcare names discussed by market analysts; useful context but no single analyst note in that article moved the story materially. Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM)…
• Negative Sentiment: A sell-side downgrade by Wall Street Zen to a “sell” rating adds downside pressure and may prompt cautious positioning from some investors. Cullinan Therapeutics (NASDAQ:CGEM) Downgraded to Sell Rating by Wall Street Zen
• Negative Sentiment: Insider Jennifer Michaelson sold 4,000 shares (about $49k at the transaction price), a continuation of prior small sales; while not large versus total insider holdings, repeated insider sales can be interpreted negatively by some investors. Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $49,200.00 in Stock

Insiders Place Their Bets

In other news, insider Jeffrey Alan Jones sold 4,632 shares of the business’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $9.67, for a total value of $44,791.44. Following the completion of the transaction, the insider owned 169,532 shares in the company, valued at $1,639,374.44. The trade was a 2.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lynx1 Capital Management Lp acquired 165,667 shares of the company’s stock in a transaction that occurred on Tuesday, October 28th. The shares were acquired at an average cost of $8.40 per share, for a total transaction of $1,391,602.80. Following the completion of the transaction, the insider directly owned 8,963,500 shares of the company’s stock, valued at $75,293,400. The trade was a 1.88% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have sold 33,420 shares of company stock worth $356,082. 7.16% of the stock is owned by corporate insiders.

Institutional Trading of Cullinan Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Signaturefd LLC raised its holdings in shares of Cullinan Therapeutics by 689.7% during the fourth quarter. Signaturefd LLC now owns 4,130 shares of the company’s stock valued at $43,000 after purchasing an additional 3,607 shares during the last quarter. SG Americas Securities LLC bought a new stake in Cullinan Therapeutics in the 3rd quarter worth approximately $62,000. Tower Research Capital LLC TRC grew its position in Cullinan Therapeutics by 44.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock worth $62,000 after purchasing an additional 2,523 shares during the period. Inscription Capital LLC purchased a new stake in Cullinan Therapeutics during the 3rd quarter valued at $67,000. Finally, Compass Ion Advisors LLC purchased a new stake in Cullinan Therapeutics during the 3rd quarter valued at $82,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics Stock Down 0.6%

Cullinan Therapeutics stock opened at $12.50 on Friday. Cullinan Therapeutics has a twelve month low of $5.68 and a twelve month high of $13.33. The company has a market capitalization of $738.45 million, a P/E ratio of -3.78 and a beta of -0.09. The stock’s 50 day moving average is $10.71 and its 200 day moving average is $8.56.

Cullinan Therapeutics (NASDAQ:CGEM) last released its earnings results on Thursday, November 6th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.18. As a group, equities analysts expect that Cullinan Therapeutics will post -3.04 EPS for the current year.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.